Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chenodiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 known ✓ | Q96RI1 | 6/20 | 0.92 |
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.92 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.92 |
| ▸ | MEN1 | O00255 | 2/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.92 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.92 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.92 |
| ▸ | LMNA | P02545 | 1/20 | 0.92 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.92 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.92 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.92 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.92 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.92 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chenodiol SCHEMBL22079588 | 0.96 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL24199134 | 0.96 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL22384718 | 0.96 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL23704676 | 0.96 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL24061005 | 0.96 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL24124587 | 0.96 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL25397934 | 0.96 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL23517166 | 0.96 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL25337643 | 0.96 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL25337648 | 0.96 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 927 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725409-A2 | METHODS AND SYSTEMS FOR VAGINAL THERAPEUTIC DEVICE FITTING | COSM Medical Corp. (CA) | 2026-04-15 | — | — | EP | claimed |
| US-12584127-B2 | Exosomes and micro-ribonucleic acids for tissue regeneration | CEDARS-SINAI MEDICAL CENTER (US) | 2026-03-24 | — | — | US | claimed |
| EP-3612191-B1 | METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCULAR DYSTROPHY | CEDARS SINAI MEDICAL CENTER (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260061097-A1 | CARDIAC FIBROBLAST DERIVED EXTRACELLULAR MATRIX | WISCONSIN ALUMNI RES FOUND (US) | 2026-03-05 | — | — | US | claimed |
| US-20250368954-A1 | MYELOID LINEAGES DERIVED FROM PLURIPOTENT CELLS | STRATUS THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250369986-A1 | APPLICATION OF BIOMARKER IN PREPARING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE CLASSIFICATION PRODUCTS | The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University (CN) | 2025-12-04 | — | — | US | claimed |
| EP-4657069-A1 | APPLICATION OF BIOMARKER IN PREPARING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE CLASSIFICATION PRODUCTS | The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University (CN) | 2025-12-03 | — | — | EP | claimed |
| US-20250346863-A1 | CELL THERAPY COMPOSITIONS AND METHODS OF MANUFACTURE | CAPRICOR INC (US) | 2025-11-13 | — | — | US | claimed |
| WO-2025230916-A1 | CELL THERAPY COMPOSITIONS AND METHODS OF MANUFACTURE | CAPRICOR, INC. (US) | 2025-11-06 | — | — | WO | claimed |
| US-12419993-B2 | Cardiac fibroblast derived extracellular matrix | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2025-09-23 | — | — | US | claimed |
| US-20220218757-A1 | THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES | CAPRICOR, INC. | 2022-07-14 | — | — | US | claimed |
| US-11357799-B2 | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy | CEDARS-SINAI MEDICAL CENTER (US) | 2022-06-14 | — | — | US | claimed |
| US-20220182133-A1 | ARCHITECTURE AND ORCHESTRATOR OF A COMMUNICATIONS SUBSYSTEM FOR A SPACE BASED SATELLITE | CALDER ALASDAIR BRUCE (US) | 2022-06-09 | — | — | US | claimed |
| US-11351200-B2 | CDC-derived exosomes for treatment of ventricular tachyarrythmias | CEDARS-SINAI MEDICAL CENTER (US) | 2022-06-07 | — | — | US | claimed |
| US-20220119813-A1 | EXOSOMES AND MICRO-RIBONUCLEIC ACIDS FOR TISSUE REGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-21 | — | — | US | claimed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | claimed |
| EP-3965800-A1 | THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES | Cedars-Sinai Medical Center (US) | 2022-03-16 | — | — | EP | claimed |
| CN-114117350-A | Carbon emission analysis method for power industry | 特斯联科技集团有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-11253551-B2 | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction | CEDARS-SINAI MEDICAL CENTER (US) | 2022-02-22 | — | — | US | claimed |
| CN-114080232-A | Extracellular vesicles for vaccine delivery | 科迪亚克生物科学公司 | 2022-02-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260061097-A1 | CARDIAC FIBROBLAST DERIVED EXTRACELLULAR MATRIX | FN1, MEF2D, CFD | NR1H4 4798/4885GPBAR1 4821/4885ABCB11 3320/4885 |
| US-12584127-B2 | Exosomes and micro-ribonucleic acids for tissue regeneration | TNNT2, TNNI3, FABP3 | NR1H4 4268/4885GPBAR1 4162/4885ABCB11 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.